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Abstract
The multiple endocrine neoplasia type 2A (MEN2A) is a monogenic disorder characterized by an autosomal dominant
pattern of inheritance which is characterized by high risk of medullary thyroid carcinoma in all mutation carriers. Although
this disorder is classified as a rare disease, the patients affected have a low life quality and a very expensive and continuous
treatment. At present, MEN2A is diagnosed by gene sequencing after birth, thus trying to start an early treatment and by
reduction of morbidity and mortality. We first evaluated the presence of MEN2A mutation (C634Y) in serum of 25 patients,
previously diagnosed by sequencing in peripheral blood leucocytes, using HRM genotyping analysis. In a second step, we
used a COLD-PCR approach followed by HRM genotyping analysis for non-invasive prenatal diagnosis of a pregnant woman
carrying a fetus with a C634Y mutation. HRM analysis revealed differences in melting curve shapes that correlated with
patients diagnosed for MEN2A by gene sequencing analysis with 100% accuracy. Moreover, the pregnant woman carrying
the fetus with the C634Y mutation revealed a melting curve shape in agreement with the positive controls in the COLD-PCR
study. The mutation was confirmed by sequencing of the COLD-PCR amplification product. In conclusion, we have
established a HRM analysis in serum samples as a new primary diagnosis method suitable for the detection of C634Y
mutations in MEN2A patients. Simultaneously, we have applied the increase of sensitivity of COLD-PCR assay approach
combined with HRM analysis for the non-invasive prenatal diagnosis of C634Y fetal mutations using pregnant women
serum.
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Introduction
Multiple endocrine neoplasia type 2 (MEN2) is composed of
three clinical subtypes, multiple endocrine neoplasia type 2A
(MEN2A), familial medullary thyroid carcinoma, and multiple
endocrine neoplasia type 2B, all of which are associated with
germline mutations in the RET proto-oncogene. Particularly,
MEN2A is an autosomal dominant hereditary syndrome caused
by mutation of the tyrosine kinase c-RET proto-oncogene on
chromosome 10q11.2 [1]. The hallmark of the disease is
medullary thyroid cancer (MTC) which occurs in nearly 100%
of cases [2] while pheochromocytoma (PHEO) is identified in 30–
50% of patients [3], and hyperparathyroidism occurs in 20% of
patients and is usually mild and manifests as only a slight elevation
of serum calcium [4]. Its prevalence is approximately 1:25.000,
accounting for more than 80% of all MEN2 cases [5]. Although
this disorder is classified as a rare disease the patients affected have
a low life quality and a very expensive and continuous treatment.
MTC represents the first clinical manifestation of MEN2
syndrome and is the principal cause of morbidity and mortality.
Early identification of MTC patients is important because of its
tendency to metastasize at an early age. Although several
biochemical tests were used for the early detection of MTC in
the past [6], it was the discovery of the correlation between
mutations of c-RET and MEN2 syndrome in 1993 that opened a
new era in the early recognition of the patients. The DNA-based
testing of the c-RET gene on a blood sample offers the opportunity
for early identification of the c-RET germline mutations, thus
contributing to the reduction of morbidity and mortality of MEN2
syndrome [7]. In fact, the early recognition of the mutant gene
carriers makes the prevention and cure of MTC possible, by
performing a prophylactic thyroidectomy before the clinical
expression of the tumor including genetic counseling [8].
The discovery of circulating cell-free DNA (cfDNA) in blood
plasma has led to a breakthrough in molecular diagnosis over the
last ten years [9]. Different hypotheses were performed to explain
the origin of cfDNA. They are supposed to derive from dead cells
due to necrosis or apoptosis [10], but some authors reported the
possibility of an active release from cells [11]. The presence of
DNA and RNA circulating freely in the blood stream of healthy
subjects can be related to activated lymphocytes and lysis of other
nucleated cells or their active secretion. In patients affected by
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e51024
neoplastic diseases it is supposed that normal and cancer cells can:
(i) detach from the tumor mass and undergo necrosis or apoptosis;
or alternatively (ii) actively release nucleic acids into the blood
flow. As regard to the biological significance of cfDNA, it has been
suggested that metastases might develop as a result of transfection
to susceptible cells in distant target organs with dominant
oncogenes that circulate in plasma and are derived from the
primary tumor [12,13]. The quantity of circulating DNA is
generally very low in healthy subjects (less than 5 ng/ml of
plasma), while it increases (5–10 times) when considering subjects
affected by neoplasic diseases [13] and in some physiologic
conditions, such as pregnancy [14] as well as in benign
pathologies.
During the last decade, cfDNA has received special attention
because of its potential application as a non-invasive, rapid, and
sensitive tool for molecular prenatal diagnosis and monitoring of
fetal pathologies since cell-free fetal DNA (cffDNA) can be
detected in maternal blood [15]. cffDNA contributes some 10%
of the DNA in maternal plasma and could be readily detected by
basic molecular techniques, being detected in maternal plasma just
weeks after conception [16,17] and is promptly cleared and
disappears within 2 h of delivery [18]. As a result, cffDNA in
maternal plasma appears to be a promising source of fetal genetic
material for the development of non-invasive prenatal diagnosis
(NIPD).
Materials and Methods
Participants and processing of serum samples
Twenty five patients diagnosed of MEN2A by standard
methods (sequencing DNA isolated from peripheral blood
leucocytes) with a C634Y mutation in c-RET gen (GeneBank
AJ243297), located on 10q11.2, were used to study the correlation
between the diagnosis by the standard method and by serum
cfDNA studies. Additionally, a healthy pregnant woman with 20
weeks of pregnancy and whose husband suffered the C634Y
mutation was also studied to determine whether measuring
cffDNA in the serum could be used for the diagnosis of the fetal
C634Y mutation. Five additional healthy subjects, negative for the
C634Y mutation, were used as controls.
Blood samples of all participants were collected by venous
puncture, centrifuged at 4uC, at 3.5006g for 10 min; then,
immediately transferred to CryoTube Vials (Nunc, Roskilde,
Denmark), and stored at -80uC until further DNA extraction. The
study was approved by the Ethical Committee of the Virgen del
Rocı´o University Hospital and has the written informed consent of
all participants.
PCR amplification and high resolution melting gene
scanning
DNA was automatically extracted from 400 mL serum using the
MagNa Pure Compact instrument (Roche Diagnostics, Bassel,
Switzerland) with the Magna Pure Compact Nucleic Acid
Isolation Kit I according to the Total NA Plasma 100 400 V3 1
extraction protocol. DNA was eluted in a final volume of 50 mL
elution buffer and stored at 280uC until used for further testing.
DNA from control positive patients was serially diluted into wild
type DNA to the following percentages (2.5, 5, 10, 20, 25, and
50%) as described by Milbury et al [19].
For the diagnosis of MEN2A in serum using cfDNA, the real
time PCR and HRM analysis were performed in the same run in a
Light Cycler 480 (Roche Applied Science, Bassel, Switzerland),
generating a product of 106 pb, containing the 634 position of the
Figure 1. Genotyping of MEN2A in serum circulating DNA. HRM analysis of 25 MEN2A patients and 5 healthy controls (red) represented as the
normalized and temperature-shifted curves converted to fluorescence different plot for analysis by the LC 480 software. HRM analysis reveals
differences in melting curve shape that correlates with patients diagnosed as MEN2A vs all controls.
doi:10.1371/journal.pone.0051024.g001
Diagnosis of MEN 2A by Cell-Free Circulating DNA
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c-RET gene exon 11. Primers used for amplification and designed
by the free Primer3 software were MEN Forward (59-
GGCGGTGCCAAGCCTCAC- 39) and MEN Reverse (59-
CACCGAGACGATGAAGGAGA- 39). PCR reactions were
performed in a total volume of 20 mL in Light Cycler plaques
with a reaction mixture containing 2 mL of eluted DNA, 0.4 mL
each primer (10 mM), 1.6 mL MgCl2 (25 mM), 5.6 mL distilled
water, and 10 mL Master Plus 480 HRM probes (Roche Applied
Science, Bassel, Switzerland). Cycling conditions were as follows: 1
cycle of 95uC for 10 min, 48 cycles of 95uC for 5 s, 65uC for 10 s,
and 72uC for 10 s. Melting analysis was at 95uC for 1 min with a
rampe rate of 4.40uC/s, 40uC for 1 min with a rampe rate of
2.20uC/s, 60uC for 1 min with a rampe rate of 4.40uC/s, and
increasing the temperature to 95uC with a rampe rate of 0.02uC/s
reading the fluorescence during this process. The last step was one
cycle of 40uC for 30 s. Result interpretation was performed using
the Light Cycler 480 Software Gene Scanning program.
For non-invasive prenatal diagnosis of MEN2A using cffDNA in
the maternal serum, a fast COLD-PCR (co-amplification at lower
denaturation temperature PCR) followed by a HRM in the same
run was performed. COLD-PCR exploits melting temperature
(Tm) differences between variant sequences and wild-type
sequences. This approach uses a critical denaturation temperature
(Tm) to selectively amplify minority mutated alleles [20]. COLD-
PCR reactions were performed in a total volume of 20 mL in Light
Cycler plaques with a reaction mixture containing 5 mL of eluted
DNA, 0.4 mL each primer (10 mM), 1.6 mL MgCl2 (25 mM),
2.6 mL distilled water, and 10 mL Master Plus 480 HRM probes
(Roche Applied Science, Bassel, Switzerland). Cycling conditions
were as follows: 1 cycle of 95uC for 10 min, 45 cycles of 95uC for
5 s, 65uC for 10 s, and 72uC for 10 s, and 20 additional cycles
changing the denaturation temperature from 95uC to 90uC (Tm).
Then, melting analysis was performed as previously shown. Result
interpretation was performed using the Light Cycler 480 Software
Gene Scanning program.
The confirmation of both HRM gene scanning and COLD-
PCR amplification results was performed by sequencing of the
PCR products (IMEGEN, Valencia, Spain).
Results
Genotyping of C634Y mutation of the ret protooncogene
by HRM analysis in serum samples
We have established HRM analysis in serum samples as a new
primary diagnosis method suitable for the detection of C634Y
mutations in exon 11 of the c-RET protooncogene. This variation
represents a heterozygous single-base substitution (exon 11, codon
634 TGC.TAC). We have analyzed serum samples of 25 patients
Figure 2. Comparison of COLD PCR and conventional HRM for non-invasive prenatal diagnosis of MEN2A. Conventional HRM (A) and
Fast COLD PCR (B) analysis of one pregnant woman with a fetus carrying the MEN2A mutation, analyzed together with negative controls and serial
dilutions of positive controls. Mutation-containing samples differ appreciably from wild-type melting curves. LC 480 software differences the
pregnant woman carrying the MEN2A fetus from the healthy controls after conventional HRM (A, red) and COLD PCR (B, green) analysis.
doi:10.1371/journal.pone.0051024.g002
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previously diagnosed by sequencing in peripheral blood leukocytes
of MEN2A with C634Y mutation. All samples were analyzed in
duplicates and plotted against 5 wild-type reference controls. After
appropriate optimization, all MEN2A patients were successfully
detected. The normalized melting curves, derivative plots, or
fluorescence different plots could be used to distinguish the C634Y
mutation from the wild-type samples (Fig. 1), showing that cfDNA
isolated from serum, rather than blood cells, could be a useful tool
for a heterozygous punctual mutation diagnosis.
Non-invasive prenatal diagnosis of C634Y mutation by
COLD-PCR and HRM
We also studied a healthy pregnant woman whose couple
suffered the C634Y mutation in heterozygosis and carried a fetus
with the MEN2A mutation. Serum samples from both negative
and positive controls were also studied. The positive control was
subjected to serial dilutions as described elsewhere. All samples
were studied by conventional HRM and by fast COLD-PCR
followed by HRM analysis. As shown In Fig. 2, HRM (A) and
COLD-PCR followed by HRM (B) analysis classified correctly the
healthy and the MEN2A positive controls. All positive control
dilutions differ from negative controls using both techniques.
However, results from COLD PCR showed more evident
differences than conventional HRM results from the lowest
dilution. Moreover, COLD PCR showed the same efficiency
when 50% to 10% dilutions were used as PCR template. The
pregnant woman carrying the MEN2A fetus was classified as
mutant, being clearly differentiated from negative controls and
placed close to 5% dilution.
Both the conventional HRM and the fast COLD-PCR products
were sequenced and results are shown in FIG. 3. Positive control
(Fig. 3A) showed the bases guanine and adenine in the 634
position in exon 11 of c-RET proto-oncogene. Although both
sequenced amplicons showed the mutated base in the position 634,
which was observed it in a mayor proportion when COLD-PCR
was performed. Negative control (Fig. 3B) shows only guanine in
the same position. The COLD-PCR product sequenced from the
pregnant woman with affected fetus (Fig. 3C) exhibited guanine
predominantly in the position 634, showing also the presence of
adenine in a quantity large enough to be detected by this method.
However, when conventional HRM was performed, only the
guanine was detected in this position.
Discussion
The determination of cfDNA is becoming a useful tool for the
diagnosis and management in various acute and chronic clinical
disorders. Changes in levels of cfDNA have been reported in
cancer, autoimmune diseases, stroke, myocardial infarction,
trauma patients, renal transplantation, virus infections, and sepsis
[21–28]. Additionally, cfDNA originated in the fetus (cffDNA) can
also be detected in the plasma of the mother from the 4th week of
pregnancy [29,30] offering a potentially superb method for early
NIPD of the genetic status of the fetus such as Rh and sex [31–33],
chromosomal aneuploidies [34], and an increasing number of
single gene disorders [35].
In this work, we study the cfDNA of 25 patients diagnosed with
MEN2A using sequencing analysis in blood cells. At the same
time, C634Y mutations were detected and, therefore, final
diagnosis was reached using HRM analysis in serum. Thus, using
this method, all MEN2A patients were successfully detected
matching 100% the results obtained by sequencing analysis.
Although the gold standard for c-RET mutation detection is
sequencing, other methods, such as single-strand conformation
polymorphism analysis, heteroduplex detection by conformation-
sensitive gel electrophoresis, restriction enzyme digestion of PCR
products, pyrosequencing, fluorescently labeled hybridization
probes, and microarrays, have also been developed to detect c-
RET mutations [36]. These methods, however, require additional
processing of the PCR products to detect mutations, misidentify
nonpathogenic polymorphisms as false positive mutations, or may
target mutation hotspots missing some rare mutations increasing
the rate of false negatives.
HRM analysis, however, is a rapid, closed-tube mutation
scanning assay that detects sequence variation within the PCR
amplicon by use of a saturating double-stranded DNA dye, and
does not require post-PCR manipulation of samples or use of
expensive labeled probes. This technique detects mutations
between the primers, in contrast to more localized techniques,
such as hybridization probes or restriction enzyme-based assays
[37]. In our study, the C634Y mutation of c-RET proto-oncogene
by HRM analysis was 100% accurate. Although not all pathogenic
c-RET mutations were available for analysis, systematic studies of
HRM detection of heterozygous point mutations within a PCR
amplicon showed a sensitivity and specificity of 100% for
amplicons ,400 bp in size [36]. Thus, HRM analysis for
Figure 3. Comparison of conventional HRM and COLD PCR
sequences of PCR products (G.A mutation). Sequence analysis of
both HRM and COLD PCR products from a positive MEN2A with C634Y
heterozygous mutation control (A), a negative healthy control (B), and
the pregnant woman carrying a fetus with the C634Y mutation (C).
doi:10.1371/journal.pone.0051024.g003
Diagnosis of MEN 2A by Cell-Free Circulating DNA
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mutation scanning is a rapid, cost-effective assay that requires no
processing or separation steps.
In the second step, a healthy pregnant woman whose couple
suffered the C634Y mutation in heterozygosis and carried a fetus
with MEN2A mutation was studied. Pregnant serum sample was
studied by fast COLD-PCR followed by HRM analysis, being this
method able to classify properly the pregnant woman with the
fetus affected from the negative controls. Thus, COLD-PCR
analysis is able to identify the cffDNA found in the pregnant
woman serum in estimated amounts of 1.5–10% [16]. COLD-
PCR selectively enriches the low-abundance mutations within a
target amplicon exploiting the small difference in amplicon
melting temperature (Tm). Just below the Tm there is a critical
denaturation temperature (Tc) wherein PCR efficiency drops
abruptly as a result of the limited number of denatured amplicons.
This difference in PCR efficiency, at specifically defined denatur-
ation temperatures, can be used to selectively enrich minority (or
low-abundance mutant) alleles throughout the course of PCR [20].
In our work, the best efficiency was obtained using the Tm as Tc,
observing that the pregnant woman carrying the MEN2A fetus
was classified as mutant, being clearly differentiated from negative
controls, and placed close to 5% dilution. Unlike the COLD PCR
study, conventional HRM analysis poorly differentiated the
pregnant woman from controls.
Other conventional method, such as Sanger sequencing, is
typically reliable for screening germline or prevalent (clonal)
somatic mutations but the sensitivity of mutation detection is
typically limited to detecting approximately 10–20% mutant
fractions [38]. In this way, after sequencing conventional HRM
PCR product from the pregnant woman with affected fetus, we
were not able to observe the presence of adenine in the position
634 in a quantity large enough to be detected by this method.
However, after COLD PCR analysis, product sequencing could
appreciate both bases (adenine and guanine) at this position. Other
method such as pyrosequencing has a sensitivity limited to
approximately 5–10% mutant in wild-type DNA [39]. Despite
the increased sensitivity that this approach provides, the equip-
ment and reagents are expensive, and it is not widely available.
Additionally to both sequence-based approaches, COLD-PCR
demonstrates the ability to identify mutants with much lower
quantity of DNA, down to 0.1% [40].
In conclusion, we have established a HRM analysis in serum
samples as a new primary diagnosis method suitable for the
detection of C634Y mutations in MEN2A patients. Simultaneous-
ly, we have applied the increase of sensitivity of COLD-PCR assay
approach combined with HRM genotyping analysis for the NIPD
of a C634Y fetal mutation using pregnant woman serum. The
results open the possibility for the use of these technologies in the
prenatal diagnosis of fetal mutations inherited from the father in a
safe manner for the fetus.
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